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Background
Population-based surveillance for malignancies in HIV-
infected patients in the antiretroviral therapy (ART) era is
warranted given the aging population of patients and the
high prevalence of risk factors in this population includ-
ing tobacco use and viral co-infections.
Methods
We identified all adult HIV-infected persons enrolled in
Kaiser Permanente (KP), an integrated health care system
providing care to ~25 percent of all Californians in the
most populated areas. Subjects at least 18 years of age at
first enrollment after 1996 were included and followed
until the earliest of an incident cancer diagnosis, last
health plan enrollment, or the end of the study period
(December 31, 2006). Incident AIDS-defining and non-
AIDS-defining cancers were ascertained from the KP can-
cer registries, which participate in the California SEER pro-
gram. Poisson regression was used to obtain age-adjusted
calendar trends in cancer incidence from 1996 to 2006.
Results are presented for KP Northern California only, but
will be updated with additional data from KP Southern
California.
Results
Between 1996 and 2006, 10,366 eligible HIV-infected
persons were identified contributing 46,114 person-years.
Subjects were mostly male (90.2%), with mean age 40
years and mean years known HIV+ of 4.1 years at study
enrollment. Subjects were 59 percent Caucasian, 17 per-
cent African-American, and 13 percent Latino. HIV expo-
sure risk factor was 65 percent men who have sex with
men, 15 percent heterosexual transmission, and 8 percent
injection drug use. A total of 394 AIDS-defining cancers
were identified consisting of 212 Kaposi's sarcomas (KS),
180 Non-Hodgkin's lymphomas (NHL), and two invasive
cervical cancers. A total of 380 non-AIDS-defining cancers
were identified. The most common non-AIDS-defining
cancers were digestive and gastrointestinal (141), consist-
ing primarily of anal (99), colorectal (22) and liver (12)
cancers; genitourinary (54), consisting primarily of pros-
tate (29) and kidney (9) cancers; head and neck cancers
(24); gynecologic cancers other than cervix (18); Hodg-
kin's lymphoma (29); lung (43); and, melanoma (32).
The AIDS-defining cancer rate/10,000 person-years
declined from 128.7 in 1996–99 to 53.9 in 2004–06, cor-
responding to a relative rate (RR) per calendar year of 0.88
(95% CI: 0.85, 0.92). KS and NHL showed similar
declines. The non-AIDS-defining cancer rate increased
from 78.9 percent in 1996 to 1999 to 97.3 percent in 2004
to 2006, corresponding to a RR per calendar year of 1.01
(95% CI: 0.98, 1.04). Most individual non-AIDS-defining
cancers showed a similar lack of a calendar trend in inci-
dence. However, there was a suggestion of an increase dur-
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ing the ART era in colorectal cancers (RR = 1.15; 95% CI =
0.99, 1.35) and genitourinary cancers (RR = 1.10; 95% CI
= 1.00, 1.21).
Conclusion
In the ART era, AIDS-defining cancers have declined and
non-AIDS-defining cancer rates have generally remained
stable. However, surveillance for non-AIDS-defining can-
cers should continue given the introduction of new thera-
peutic classes with the potential for oncogenic side effects,
and the fact that HIV-infected patients continue to have
increased rates of many cancers compared to the general
population.Page 2 of 2
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